Cargando…
Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-epi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358648/ https://www.ncbi.nlm.nih.gov/pubmed/25834440 http://dx.doi.org/10.2147/NDT.S80746 |
_version_ | 1782361273940312064 |
---|---|
author | Masopust, Jiří Andrýs, Ctirad Bažant, Jan Vyšata, Oldřich Kuca, Kamil Vališ, Martin |
author_facet | Masopust, Jiří Andrýs, Ctirad Bažant, Jan Vyšata, Oldřich Kuca, Kamil Vališ, Martin |
author_sort | Masopust, Jiří |
collection | PubMed |
description | BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-episode schizophrenia. In our work, we investigated the presence of antibodies against NMDA-R in patients with first-episode psychosis (FEP) in comparison with healthy volunteers. METHODS: This study included 50 antipsychotic-naïve patients with FEP (including 21 women) and 50 healthy volunteers (including 21 women). The mean age of the patients was 27.4 (±7.4) years and that of the healthy controls was 27.0 (±7.3) years. Antibodies against NMDA-R in the serum were detected by immunofluorescence. RESULTS: None of the investigated patients with an FEP and none of the healthy controls showed positive antibodies against NMDA-Rs. CONCLUSION: According to results of studies, a small proportion of patients with an FEP possess antibodies against NMDA-R. However, the extent to which this finding contributes to the etiopathogenesis of the response to antipsychotic medication and whether immunomodulatory therapy is indicated in these cases remains uncertain. |
format | Online Article Text |
id | pubmed-4358648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43586482015-04-01 Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia Masopust, Jiří Andrýs, Ctirad Bažant, Jan Vyšata, Oldřich Kuca, Kamil Vališ, Martin Neuropsychiatr Dis Treat Original Research BACKGROUND: Encephalitis with antibodies against N-methyl-D-aspartate receptor (NMDA-R) is classified as an autoimmune disorder with psychotic symptoms, which are frequently dominant. However, it remains unclear how frequently NMDA-R antibodies lead to a condition that mimics psychosis and first-episode schizophrenia. In our work, we investigated the presence of antibodies against NMDA-R in patients with first-episode psychosis (FEP) in comparison with healthy volunteers. METHODS: This study included 50 antipsychotic-naïve patients with FEP (including 21 women) and 50 healthy volunteers (including 21 women). The mean age of the patients was 27.4 (±7.4) years and that of the healthy controls was 27.0 (±7.3) years. Antibodies against NMDA-R in the serum were detected by immunofluorescence. RESULTS: None of the investigated patients with an FEP and none of the healthy controls showed positive antibodies against NMDA-Rs. CONCLUSION: According to results of studies, a small proportion of patients with an FEP possess antibodies against NMDA-R. However, the extent to which this finding contributes to the etiopathogenesis of the response to antipsychotic medication and whether immunomodulatory therapy is indicated in these cases remains uncertain. Dove Medical Press 2015-03-06 /pmc/articles/PMC4358648/ /pubmed/25834440 http://dx.doi.org/10.2147/NDT.S80746 Text en © 2015 Masopust et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Masopust, Jiří Andrýs, Ctirad Bažant, Jan Vyšata, Oldřich Kuca, Kamil Vališ, Martin Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title | Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title_full | Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title_fullStr | Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title_full_unstemmed | Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title_short | Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia |
title_sort | anti-nmda receptor antibodies in patients with a first episode of schizophrenia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358648/ https://www.ncbi.nlm.nih.gov/pubmed/25834440 http://dx.doi.org/10.2147/NDT.S80746 |
work_keys_str_mv | AT masopustjiri antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia AT andrysctirad antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia AT bazantjan antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia AT vysataoldrich antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia AT kucakamil antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia AT valismartin antinmdareceptorantibodiesinpatientswithafirstepisodeofschizophrenia |